Iovance Biotherapeutics, Inc. Earnings

Iovance Biotherapeutics, Inc.’s revenue jumped 6798.46% since last year same period to $49.32Mn in the Q1 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated -33.07% fall in its revenue since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit fell -2.82% since last year same period to $-116.16Mn in the Q1 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated -47.87% fall in its net profits since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit margin jumped 98.51% since last year same period to -235.51% in the Q1 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated -120.93% fall in its net profit margins since last 3-months.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 7.46% jump from last quarter’s estimates.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.26.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Iovance Biotherapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.